Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML

Research output: Contribution to journalArticle

93 Scopus citations
Original languageEnglish (US)
Pages (from-to)8541-8546
Number of pages6
JournalOncogene
Volume21
Issue number56 REV. ISS. 7
DOIs
StatePublished - Dec 9 2002

Keywords

  • Bcr-Abl
  • CML
  • Inhibitor
  • STI571
  • Tyrosine kinase

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this